- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nautilus Biotechnology Inc (NAUT)
Nautilus Biotechnology Inc stock price live, this page displays NASDAQ NAUT stock exchange data. View the NAUT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nautilus Biotechnology Inc real time stock price chart below.
What Is the Nautilus Biotechnology Inc Stock Price Today?
The Nautilus Biotechnology Inc stock price today is 2.030.
What Is the Stock Symbol for Nautilus Biotechnology Inc?
The stock symbol for Nautilus Biotechnology Inc is ""NAUT.""
What Stock Exchange Does Nautilus Biotechnology Inc Trade On?
Nautilus Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Nautilus Biotechnology Inc a Good Stock to Buy?
Determining whether Nautilus Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAUT quote. (ISIN: US63909J1088)
What Is the Nautilus Biotechnology Inc Stock Price Today?
The Nautilus Biotechnology Inc stock price today is 2.030.
What Is the Stock Symbol for Nautilus Biotechnology Inc?
The stock symbol for Nautilus Biotechnology Inc is ""NAUT.""
What Stock Exchange Does Nautilus Biotechnology Inc Trade On?
Nautilus Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Nautilus Biotechnology Inc a Good Stock to Buy?
Determining whether Nautilus Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAUT quote. (ISIN: US63909J1088)
Fair Value
An estimate of a Nautilus Biotechnology's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.970
2.080
52 wk Range
0.620
2.540
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Nautilus Biotechnology's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9702.080
52 wk Range
0.6202.540
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAUT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Nautilus Biotechnology's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
2.500
Upside
+23.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Nautilus Biotechnology Inc Company Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes an end-to-end solution comprising instruments, consumables, and software analysis. It also offers a proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffer system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. and Weill Cornell Medicine—Qatar have a research collaboration with The Michael J. Fox Foundation to study the connection between the alpha-synuclein (aSyn) protein and Parkinson’s disease (PD). Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology Inc Earnings Call Summary for Q3/2025
- Nautilus Biotechnology (NAUT) beat Q3 2025 EPS expectations with -$0.11 vs -$0.15 forecast, leading to a 10.66% pre-market stock surge
- Operating expenses reduced by 19% YoY to $15.5M, with R&D expenses down 22%; net loss improved to $13.6M from $16.4M last year
- Company plans to launch TAU proteoform assay early access program in H1 2026, with broader commercial launch later that year
- CEO Sujal Patel emphasized platform's disruptive potential in proteomics, potentially replacing significant portions of existing technologies
- Anticipates increased operating expenses approaching commercialization; maintains strong cash position of $168.5M
Last Updated: 28/10/2025, 14:28
Read Full TranscriptCompare NAUT to Peers and Sector
Metrics to compare | NAUT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAUTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −2.0x | −0.5x | |
PEG Ratio | −0.37 | 0.00 | 0.00 | |
Price/Book | 1.5x | 1.0x | 2.6x | |
Price / LTM Sales | - | 3.7x | 3.3x | |
Upside (Analyst Target) | 23.2% | 32.3% | 45.8% | |
Fair Value Upside | Unlock | 10.1% | 6.4% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 2.500
(+23.15% Upside)
Earnings
Latest Release
Oct 28, 2025
EPS / Forecast
-0.11 / -0.15
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Nautilus Biotechnology (NAUT) Premarket Price Today?
The Nautilus Biotechnology (NAUT) premarket price is 2.050. Premarket price change units: 0.030. Premarket percentage change: 1.490%. Premarket volume: 810.000. Current date: 08 Feb 2026. Previous close: 2.020
What Is the Stock Symbol for Nautilus Biotechnology?
The stock symbol for Nautilus Biotechnology is "NAUT."
What Is the Nautilus Biotechnology Market Cap?
As of today, Nautilus Biotechnology market cap is 256.40M.
What Is Nautilus Biotechnology's Earnings Per Share (TTM)?
The Nautilus Biotechnology EPS (TTM) is -0.50.
When Is the Next Nautilus Biotechnology Earnings Date?
Nautilus Biotechnology will release its next earnings report on 25 Feb 2026.
From a Technical Analysis Perspective, Is NAUT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Nautilus Biotechnology Stock Split?
Nautilus Biotechnology has split 0 times.
How Many Employees Does Nautilus Biotechnology Have?
Nautilus Biotechnology has 124 employees.
What is the current trading status of Nautilus Biotechnology (NAUT)?
As of 08 Feb 2026, Nautilus Biotechnology (NAUT) is trading at a price of 2.030, with a previous close of 2.020. The stock has fluctuated within a day range of 1.970 to 2.080, while its 52-week range spans from 0.620 to 2.540.
What Is Nautilus Biotechnology (NAUT) Price Target According to Analysts?
The average 12-month price target for Nautilus Biotechnology is USD2.500, with a high estimate of USD2.5 and a low estimate of USD2.5. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.15% Upside potential.
What Is the NAUT Premarket Price?
NAUT's last pre-market stock price is 2.050. The pre-market share volume is 810.000, and the stock has decreased by 0.030, or 1.490%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.